US FDA approves Avacta Group’s IND application for AVA6000
The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin. With this approval
The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin. With this approval
Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform. SV Health
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the use of Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, in children
Health Canada has granted full approval to Janssen Pharmaceutical Companies of Johnson & Johnson’s single-dose Covid-19 vaccine for the disease prevention in people aged 18 years and above.
The first-in-class Trop-2-directed antibody-drug conjugate was approved for use on TNBC patients who have received at least two systemic therapies including one or more for advanced disease. The
This licensing deal will see Sanofi leverage the LinearDesign platform that will lead to the optimisation of mRNA sequences for human therapeutic and preventive uses. Furthermore, this agreement
The expanded EUA allows the administration of booster dose to individuals of 18 years of age and older who have received primary dosages. With the same dosage strength
Danish pharma company Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals and its ribonucleic acid interference (RNAi) platform in a deal valued at $3.3bn, to expand the RNAi
Pfizer has secured a contract worth $5.29bn from the US government to supply its experimental Covid-19 oral antiviral drug, Paxlovid (PF-07321332; ritonavir). Designed to hinder the SARS-CoV-2-3CL protease
GlaxoSmithKline (GSK) and Vir Biotechnology have secured contracts from the US government for nearly $1bn to supply their Covid-19 antibody treatment, sotrovimab. Sotrovimab is an investigational single-dose SARS-CoV-2